Results from the monarchE trial showed that the addition of 2 years of abemaciclib to endocrine therapy significantly improved iDFS in patients with HR+/HER2-, lymph node-positive, high-risk, early-stage breast cancer (33). The gene discussed is ERBB2; the disease is breast cancer.